
    
      This Phase I study is designed as a pilot trial evaluating the safety and of CD19-STAR-T cell
      therapy in subjects with refractory and relapsed B cell malignancies. Subjects will receive
      cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3
      followed by infusion of CD19-STAR-T cells. Safety and efficacy of CD19-STAR-T cells therapy
      will be monitored. The purpose of current study is to determine the clinical efficacy and
      safety of CD19-STAR-T cells therapy in patients with refractory and relapsed B-cell
      malignancies.
    
  